| 词条 | Lazabemide |
| 释义 |
| IUPAC_name = N-(2-aminoethyl)-5-chloro-pyridine-2-carboxamide | image = Lazabemide.svg | tradename = | pregnancy_category = | legal_status = Development terminated | routes_of_administration = Oral | bioavailability = | metabolism = | elimination_half-life = | excretion = | IUPHAR_ligand = 6640 | CAS_number = 103878-84-8 | ATC_prefix = none | ATC_suffix = | PubChem = 71307 | ChemSpiderID = 64426 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 420HD787N9 | KEGG = D04681 | C=8 | H=10 | Cl=1 | N=3 | O=1 | molecular_weight = 199.64 g/mol }}Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.[1] References1. ^{{cite journal |vauthors=Henriot S, Kuhn C, Kettler R, Da Prada M | title = Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings. | journal = J Neural Transm Suppl | volume = 41 | pages = 321–325 | year = 1994 | pmid = 7931245 }} {{Antiparkinsonian}}{{Monoamine metabolism modulators}}{{nervous-system-drug-stub}} 5 : Abandoned drugs|Monoamine oxidase inhibitors|Chloroarenes|Pyridines|Carboxamides |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。